Cancer Medical Cannabis Studies

• View All (505)

Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors (2003)

This study aims to verify the inhibition of the growth of skin tumors and angiogenesis in vivo by activation of cannabinoid receptors. The results of this investigation give a new therapeutic approach for the treatment of skin tumors. View study
Inhibition of tumor angiogenesis by cannabinoids (2003)

Active angiogenesis is causally involved in the progression of most solid tumors. For this reason a great effort is being made in the development of effective antiangiogenic drugs to treat cancer. With respect to the study of the therapeutic effects of cannabinoids, the findings of this study show that these compounds can be considered promising anti-tumor agents, since they inhibit tumor angiogenesis and growth in vivo without significant side effects. However, more research is needed to elucidate these molecular mechanisms. View study
Integrating cannabis into clinical cancer care (2016)

Cannabis and cannabinoids are useful for controlling symptoms related to cancer and its treatment. Cannabinoids may be synergistic with opioids in pain relief. The safety profile of cannabis is acceptable, with side effects that are generally tolerable and of short duration. Preclinical data suggest that cannabinoids may have a direct antitumor activity. Oncologists could find cannabis and cannabinoids as effective tools to care for patients living with cancer and beyond it. However, in-depth human studies should be carried out in order to verify the effectiveness of cannabinoids in the treatment of cancer. View study
Involvement of PPARc in the antitumoral action of cannabinoids on hepatocellular carcinoma (2013)

The cannabinoids D9-tetrahydrocannabinol and JWH-015 have the ability to exert an antitumor effect against human hepatocellular carcinoma cell lines HepG2 and HUH-7 in vitro and in vivo through PPARg (peroxisome proliferator-activated gamma receptor). View study
Loss of Cannabinoid Receptor 1 Accelerates Intestinal Tumor Growth (2008)

Aberrant methylation of the cannabinoid receptor 1 (CB1) represents a clear mechanism for combating colorectal cancer (CRC). Through different approaches, in vivo evidence was found that shows that endocannabinoid signaling through CB1 plays a key role in the regulation of intestinal tumor growth. These results may provide a rationale for the development of CB1 agonists that do not cross the blood-brain barrier and that can be used to prevent and treat cancer in combination with a demethylating agent. View study
Marijuana Use and the Risk of Lung and Upper Aerodigestive Tract Cancers: Results of a Population-Based Case-Control Study (2006)

These studies indicate that marijuana is not carcinogenic or has a percentage well below the practically detectable limits to be, in opposition to various lines of evidence suggesting otherwise. View study
Medical marijuana for cancer (2015)

Pharmaceutical cannabis and cannabinoid products can be useful for a large number of problems, including many that affect cancer patients. High-quality marijuana and cannabinoid pharmaceutical studies in the treatment of a range of medical conditions would better clarify the clinical effects of the various strains of marijuana and the bioactive compounds found therein. Differences in pharmacokinetics between oral ingestion and inhalation may point to differences in clinical effect for different indications. For example, given the limitations inherent in the use of oral medications to treat nausea and vomiting, the inhalation of marijuana or a cannabinoid may be better than oral ingestion to treat this condition. View study
Medical Marijuana Use in a Community Cancer Center. (2018)

The objective of the present investigation was to compare the incidence of marijuana use among patients with early versus advanced cancer. It was concluded that approximately one out of every five cancer patients receiving chemotherapy was using marijuana, and the frequency was the same in the early and advanced stage cancer groups. View study
Medicinal cannabis in oncology (2007)

This review focused on analyzing the background of the introduction of legal medical cannabis in the Netherlands, the last years of Dutch clinical experience in the practice of oncology, the possible reasons that underlie the current result and future prospects. View study
Melanoma: Assessment and Management (2015)

Cutaneous melanoma is increasing in incidence in many of the developed countries, since this form of cancer occurs predominantly in people with pale skin who are exposed to intense sunlight. Male sex and age are two factors of poor prognosis for melanoma. This study focused on the evaluation and management of Melanoma. View study
Microarray and Pathway Analysis Reveal Distinct Mechanisms Underlying Cannabinoid-Mediated Modulation of LPS-Induced Activation of BV-2 Microglial Cells (2013)

Cannabidiol (CBD) can elicit robust responses that are related to oxidative stress and inflammation. In addition, CBD and, to a lesser extent, D9-tetrahydrocannabinol (THC), have protective activities and decrease the immunological activity of the organism in response to medical treatment. View study
Nausea and Vomiting Related to Cancer Treatment (PDQ�): Patient Version (2018)

Nausea and vomiting can occur with many treatments for cancer. The nausea causes nausea in the stomach, as if the food he ate went up again. This summary aims to inform about cancer with updated information on the causes and treatment of nausea and vomiting (emesis) (N & V). It is meant to inform and help patients, families and caregivers. View study